TB-500vsTesamorelin + Ipamorelin

TB-500 is the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide present in virtually every nucleated cell in the body. Its central molecular function is the sequestration of G-actin monomers — the globular, unpolymerized form of actin. By binding G-actin at a 1:1 ratio, TB-500 maintains a reservoir of monomeric actin that can be rapidly mobilized for polymerization into F-actin filaments when cells need to migrate, change shape, or form new structures during tissue repair.

This actin-regulating role is fundamental to TB-500's healing effects. When tissue is damaged, cells at the wound margin must migrate into the injury site. Cell migration requires dynamic actin polymerization at the leading edge of the cell (forming lamellipodia and filopodia) and depolymerization at the trailing edge. TB-500 facilitates this process by providing a controlled supply of G-actin monomers. It promotes migration of keratinocytes (for skin wound closure), endothelial cells (for new blood vessel formation), and cardiac progenitor cells (for heart repair).

Beyond actin regulation, TB-500 has significant anti-inflammatory and gene-regulatory effects. It downregulates pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α while upregulating anti-inflammatory mediators. It activates cell survival pathways, specifically Akt-mediated anti-apoptotic signaling, protecting damaged cells from programmed cell death. TB-500 also promotes angiogenesis by stimulating endothelial progenitor cell differentiation and new capillary formation. In cardiac tissue, it has demonstrated the ability to activate epicardial progenitor cells and promote cardiomyocyte survival following ischemic injury. The combination of cell migration, anti-inflammation, angiogenesis, and cell survival makes TB-500 one of the most broad-spectrum healing peptides available.

The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.

The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.